Tideglusib attenuates growth of neuroblastoma cancer stem/progenitor cells in vitro and in vivo by specifically targeting GSK-3β.
Hisham F BahmadReda M ChalhoubHayat HaratiJolie Bou-GhariosSahar AssiFarah BalloutAlissar MonzerHiba MsheikTarek ArajiMohamad K ElajamiPaola GhanemFarah ChamaaHumam KadaraTamara Abou-AntounGeorges DaoudYoussef FaresWassim Abou KheirPublished in: Pharmacological reports : PR (2020)
Collectively, we concluded that TDG could serve as an effective treatment capable of targeting the NB CSCs and hence overcoming therapy resistance. Yet, future studies are warranted to further investigate its potential role in NB and decipher the subcellular and molecular mechanisms underlying this role.